Description

Mazdutide Peptide — MedLabs Peptides

⚠️ For Laboratory Use Only: This product, mazdutide peptide, is intended strictly for controlled research and analytical purposes.

What Is Mazdutide?

The mazdutide peptide — also known by its other name, IBI362 — is a once-weekly dual receptor agonist developed through a collaboration between Innovent Biologics and Eli Lilly. It targets both the GLP-1 receptor and the glucagon receptor (GCGR) simultaneously, giving it a broader metabolic reach than single-receptor compounds.

So, what is mazdutide used for? Researchers study it primarily for two major conditions — obesity and type 2 diabetes. Its dual-action design helps reduce body weight significantly while also improving glycemic control.

This makes the mazdutide peptide one of the most exciting compounds in current metabolic research.

Is Mazdutide a GLP-1 Agonist?

Yes — and it goes further than that. The mazdutide peptide activates both the GLP-1 receptor and the glucagon receptor (GCGR). This dual activation sets it apart from standard GLP-1 agonists like semaglutide or liraglutide.

By targeting glucagon receptors alongside GLP-1 receptors, mazdutide drives stronger fat burning, better energy expenditure, and more robust weight reduction. Researchers classify it as a GLP-1R/GCGR dual agonist — a next-generation approach to metabolic therapy.

What Is the Other Name for Mazdutide?

Mazdutide carries the research designation IBI362. You may encounter both names across clinical literature and research databases. At MedLabs Peptides, we supply this compound under its widely recognized name — mazdutide — for easy identification across research applications.

How the Mazdutide Peptide Works

The mazdutide peptide delivers its effects through two simultaneous pathways:

• GLP-1 Receptor Activation — Stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite.
• Glucagon Receptor Activation — Boosts energy expenditure and accelerates fat breakdown, amplifying the overall weight loss effect.

Together, these two pathways create a powerful and well-studied metabolic response. Researchers find this dual mechanism particularly valuable for studying obesity with concurrent metabolic complications.

Mazdutide Clinical Trial Results

The mazdutide peptide has generated impressive data across multiple clinical trials, particularly in Chinese adult populations. Here are the key highlights:

GLORY-2 Study

The 9 mg dose of mazdutide produced up to 20.1% body weight reduction in Chinese adults living with obesity. This result places mazdutide among the highest-performing weight loss compounds in current research.

Type 2 Diabetes Study

At the 6 mg dose, mazdutide delivered effective weight reduction and meaningful HbA1c improvements in Chinese patients managing type 2 diabetes. Results consistently outperformed placebo across all measured endpoints.

Phase 1b Safety Study

Early-phase research confirmed that the mazdutide peptide is well-tolerated. Researchers recorded no serious adverse events, building a strong safety foundation for ongoing Phase 3 investigations.

What Is Mazdutide Used For? — Key Research Benefits

MedLabs Peptides supplies mazdutide to support research across several critical areas:

Weight Loss Efficacy

Studies show that 24-week mazdutide treatment protocols produce weight reductions exceeding 10% of body weight in a large proportion of participants. This makes it a top-tier compound for obesity research.

Glycemic Control

The mazdutide peptide actively lowers HbA1c levels — a key marker of long-term blood sugar regulation. Researchers studying type 2 diabetes find this benefit particularly valuable.

Cardiovascular Benefits

Beyond weight and glucose, clinical data link mazdutide to measurable cardiovascular improvements. This positions the compound as a multi-benefit research tool for cardiometabolic studies.

What Is Mazdutide for Men?

Research on mazdutide for men focuses on reducing visceral fat — the deep abdominal fat strongly associated with cardiovascular disease and insulin resistance. Men in clinical studies show strong responses in body composition metrics, making mazdutide highly relevant to male metabolic health research.

Mazdutide vs Tirzepatide — How Do They Compare?

Both compounds target GLP-1 receptors, but they differ in their secondary targets:

Feature	Mazdutide (IBI362)	Tirzepatide
Primary Target	GLP-1R + GCGR	GLP-1R + GIPR
Developer	Innovent / Eli Lilly	Eli Lilly
Dosing Frequency	Once weekly	Once weekly
Weight Loss (Peak)	Up to 20.1%	Up to 22.5%
Key Population Studied	Chinese adults	Global populations

Mazdutide vs tirzepatide comes down to receptor targeting — mazdutide activates glucagon receptors while tirzepatide activates GIP receptors. Each pathway drives weight loss through slightly different mechanisms, making both compounds valuable in comparative metabolic research.

Mazdutide vs Retatrutide — Triple vs Dual Agonist

Mazdutide vs retatrutide represents a key research comparison. Retatrutide targets three receptors — GLP-1R, GIPR, and GCGR — making it a triple agonist. Mazdutide targets two — GLP-1R and GCGR.

Retatrutide produces slightly higher peak weight loss in early studies. However, mazdutide’s dual-agonist profile offers a cleaner mechanism for researchers seeking to isolate the specific contributions of GLP-1 and glucagon receptor activation.

Side Effects — What Researchers Observe

The mazdutide peptide produces a mild-to-moderate side effect profile, consistent with other GLP-1-based compounds. Researchers document the following most frequently:

Side Effect	Severity
Nausea	Mild to Moderate
Diarrhea	Mild to Moderate
Vomiting	Mild to Moderate
Decreased Appetite	Mild

Importantly, these effects typically appear early in the dosing schedule and reduce over time. Researchers also note that mazdutide may influence the absorption of oral medications taken concurrently, due to its gastric-emptying effects.

Mazdutide Pricing & Regulatory Status

Mazdutide does not yet carry an official commercial price, as it remains in clinical trial stages. Currently, China’s National Medical Products Administration (NMPA) evaluates the 9 mg dosage for regulatory approval.

Researchers and institutions looking to buy mazdutide for laboratory use can source a research-grade supply directly through MedLabs Peptides.

Where to Buy Mazdutide

MedLabs Peptides provides researchers with reliable access to the mazdutide peptide in research-grade form. Every vial meets strict quality and purity standards to support consistent, reproducible research outcomes.

When you choose MedLabs Peptides as your mazdutide supplier, you get:

•  Research-grade purity
•  Sterile, sealed vials
•  Consistent batch quality
•  Dependable supply for long-term studies

Storage & Handling of Mazdutide Peptide

Proper storage protects the integrity of the mazdutide peptide. Follow these guidelines:

• Temperature: -20°C to 4°C (4°F to 39°F)
• Environment: Dry conditions, away from direct sunlight and heat
• Handling: Follow all standard sterile laboratory protocols for peptide compounds

Research Applications at MedLabs Peptides

MedLabs Peptides supplies the mazdutide peptide to support investigation across these key research areas:

• Obesity and excess body fat reduction studies
• Type 2 diabetes and HbA1c regulation research
• Dual GLP-1R/GCGR agonist mechanism studies
• Cardiovascular risk reduction in metabolic disease
• Comparative studies against tirzepatide and retatrutide